S'abonner

Classification of facial psoriasis based on the distributions of facial lesions - 24/04/13

Doi : 10.1016/j.jaad.2008.02.006 
Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo, MD, Jai Il Youn, MD, PhD
Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea 

Reprint requests: Jai Il Youn, MD, PhD, Department of Dermatology, Seoul National University College of Medicine, 28-Yongon-dong, Chongno-gu, Seoul 110-744, Korea.

Abstract

Background

Psoriasis is a common chronic inflammatory skin disease that may involve any skin site. In particular, psoriasis on the face gives rise to considerable concern because of associated cosmetic problems and psychosocial distress. Some authors have reported that a significant proportion of patients with psoriasis have facial involvement, and several reports have suggested that facial involvement is a marker of severe psoriasis. However, patients with facial psoriasis seem to have clinical characteristics that depend on the distributions of their facial lesions.

Objective

We sought to classify facial psoriasis and evaluate clinical characteristics according to the distribution of facial psoriatic lesions, and to compare the severities of body and scalp psoriasis in patients with central or peripheral facial lesions.

Methods

A total of 194 patients with psoriasis with facial involvement who presented at our psoriasis clinic were enrolled in this study. Onset of psoriasis, family history, history of phototherapy or systemic therapy, and admission history were recorded. Severity of psoriasis on whole body, face, and scalp were rated using Psoriasis Area and Severity Index (PASI) scores. Patients were categorized into 3 types according to facial lesion distribution: peripherofacial type (PF) (upper forehead and/or periauricular lesions), centrofacial type, and mixed type.

Results

The PF and mixed type were more common than the centrofacial type. Peripherofacial involvement was related to a high scalp PASI score, whereas centrofacial involvement was associated with a high whole body PASI score. Disease duration before facial lesion development was less for the PF. Early onset of disease and extensive treatment were more frequent for centrofacial type than PF. The relationship between facial and body psoriasis progression was less strong for PF.

Limitations

This was a retrospective study conducted at a single location, and the severity and extent of psoriasis were evaluated only once, at first visits.

Conclusion

Facial psoriasis can be categorized into 3 different types. Peripherofacial involvement might be a consequence of severe scalp psoriasis, whereas centrofacial involvement might be a marker of severe body psoriasis. Thus, it would help during the treatment of patients with psoriasis to consider that different lesion distributions may reflect different clinical characteristics.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : CF, MF, PASI, PF, UV


Plan


 Funding sources: None.
 Conflicts of interest: None declared.
 Presented at 11th Annual Meeting of the Korean Society of Psoriasis in Seoul, Korea, on May 19, 2007. Submitted as a poster at the 21st World Congress of Dermatology in Buenos Aires, Argentina, from September 30 to October 5, 2007.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 58 - N° 6

P. 959-963 - juin 2008 Retour au numéro
Article précédent Article précédent
  • IgG anti-laminin-332 autoantibodies are present in a subset of patients with mucous membrane, but not bullous, pemphigoid
  • Zelmira Lazarova, Valerie K. Salato, Christoph M. Lanschuetzer, Marleen Janson, Janet A. Fairley, Kim B. Yancey
| Article suivant Article suivant
  • Psoriasis treatment patterns: Results of a cross-sectional survey of dermatologists
  • Vaishali Patel, Elizabeth J. Horn, Steve J. Lobosco, Kathleen M. Fox, Seth R. Stevens, Mark Lebwohl

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.